While FOLFOX has been proven effective for treating stage III and IV CRC, FOLFOX might not be suitable for treating high-risk stage II CRC harbouring BRAF V660E mutation with or without microsatellite stable (MSS) status due to a higher chance of tumour relapse after treatment (Seppälä et al., 2015). Here, BRAF is linked to colorectal carcinoma.